MIMEDX Announces Third Quarter 2026 Operating & Financial Results
MiMedx reported Q3 2026 net sales of $62.3 million, down 45% year-over-year, as Wound segment sales fell 71% under the January 2026 Medicare reimbursement changes, producing a GAAP net loss of $8.7 million (diluted EPS of -$0.06) versus $16.7 million net income a year ago. Offsetting the decline, Surgical sales grew 9% to nearly two-thirds of net sales, gross margin improved sequentially to 80%, the company returned to positive Adjusted EBITDA of $2.1 million, repaid its remaining $17 million term loan, and lowered FY26 sales guidance to $250-260 million.
Key figures
- Revenue
- 62283000
- Guidance
- FY2026 net sales $250-$260 million; Q4 Adjusted EBITDA expected sequentially higher than Q3; longer-term low double-digit annual sales growth with Adjusted EBITDA margin above 20%
- Revenue Yoy
- -45%
- Fcf
- 3753000
- Sga
- 58313000
- Cash
- 120791000
- Rd expense
- 2796000
- Gross margin
- 80%
- Gross profit
- 49702000
- Adjusted ebitda
- 2066000
- Wound sales decline
- -71%
- Surgical sales growth
- 9%
- Adjusted ebitda margin
- 3.3%
- Wound care center volume growth sequential
- 7%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.